Consulting, Affiliated & Adjunct Faculty
Victor Tse, MD, PhD
Consulting Associate Professor
Victor Tse MD PhD completed his undergraduate and medical training at Clare College and the School of clinical medicine, Cambridge University, England. He finished his PhD in Imperial College of Medicine and Advance Sciences and Technology, University of London. He finished his Neurology and Neurosurgery residency at Stanford. He has written extensively on tumor angiogenesis and the microenvironment.
Yaisa S. Andrews-Zwilling, PhD
Consulting Assistant Professor
Dr. Andrews-Zwilling is originally from Trinidad-Tobago, where she completed her B.Sc. in Biochemistry and Chemistry. From there she went to train at the prestigious Max Planck Institute for Experimental Medicine in Gottingen, Germany, where she received both her M.Sc. and Ph.D. in Neuroscience. Dr. Andrews-Zwilling made important contributions to the field of synapse formation/communication between nerve cells during her Ph.D.
She then joined the Gladstone Institutes, where she turned her efforts to studying the role of apoE4, the major risk factor which predisposes individuals to getting Alzheimer’s disease and also causes poorer recovery after traumatic brain injury and stroke. Dr. Andrews-Zwilling later focused her research toward developing drugs that block the detrimental effects of apoE4 on nerve cells at the Gladstone.
Dr. Andrews-Zwilling is currently the Assoc. Director of Research at SanBio Inc., a company which develops regenerative therapies, using adult stem cells, for neurological disorders, including stroke, traumatic brain injury, spinal cord injury and retinal degeneration. Dr. Andrews-Zwilling is also a Consulting Professor at Stanford University.
Dr. Andrews-Zwilling is the recipient of many awards including the Award for Young Scientists from the Alzheimer’s Association and the National Award for Excellence in Science from the National Institute of Higher Education, Research, Science and Technology, the Ministry of Science and Technology and the Caribbean Academy of Sciences.
Abdulrazag Ajlan, MD
Adjunct Clinical Assistant Professor
Abdulrazag Ajlan specializes in neuro-oncology and skull-based neurosurgery, with an interest in endoscopic procedures. After earning a master's degree in molecular biology, he completed his residency at Montreal, McGill University (Montreal Neurological Institute). He then studied for three years under Dr. Griffith Harsh and Dr. Lawrence Recht at Stanford. Abdul is currently a full-time faculty member at King Saud University, Riyadh, Saudi Arabia and an adjunct professor at Stanford.
Robert Booth, PhD
Robert Booth completed his undergraduate studies and obtained his PhD in biochemistry from the University of London. He has extensive experience in drug discovery and development within the biopharmaceutical industry. He has also operated within the venture capital industry. He is currently the CEO of Virobay Inc. and serves on the boards of Cymabay Therapeutics, Ab Initio Biotherapeutics and Glialogix.
Donald J. Prolo, MD
Clinical Adjunct Professor
Donald J. Prolo, graduated from Stanford University in 1957 with a Bachelor of Arts degree (with Great Distinction), Departmental Honors in Biological Sciences and membership in Phi Beta Kappa. He achieved his MD degree at Stanford in 1961, having become a member of Alpha Omega Alpha Honor Medical Society in 1960. After a surgical internship at Johns Hopkins Hospital in Baltimore he completed neurosurgical residency at Stanford in 1970 and was certified by the American Board of Neurological Surgery in 1972. He continued on the full-time faculty one year as Chief of Neurosurgery, Valley Medical Center, founded the Neuroskeletal Transplantation Laboratory and the third human bone and soft tissue bank in the United States, Western Transplantation Services, at the California Institute for Medical Research. He subsequently continued transplantation research while in private neurosurgical practice in San Jose.
On October 1, 1969 at the Palo Alto Veterans Administration Hospital he pioneered the field of endovascular neurosurgery by being the first to treat an abnormal intracranial condition indirectly through only an extracranial artery with the use of a catheter. Major intracranial surgery was thereby avoided by introducing a balloon through the cervical carotid artery to the site of this arteriovenous malformation, a carotid-cavernous fistula (Journal of Neurosurgery, August, 1971). Subsequently he designed a catheter, which was used throughout the world for treatment of this condition. (Surgical Neurology, April 1977).
In two JAMA papers published April 30, 1973, he reported his designed Cervical Stabilization-Traction Board for immediate immobilization of the injured cervical spine at injury site and an early unique series of patients with unstable spines utilizing the halo device for immediate and long-term halo-thoracic and halo-pelvic stabilization.
He pioneered the transplantation of human cadaver bone and soft tissues in surgery with basic contributions resulting from canine research and human applications. These contributions included methods of safe, effective sterilization of allogeneic tissues and their subsequent successful incorporation in canine studies and human applications. His Neuroskeletal Transplantation Laboratory distributed to neurosurgical, orthopedic and reconstructive surgeons throughout the United States over 50,000 allografts for patients over 20 years (1975-1995) without a single report of bacterial, fungal or viral infection, transmitted by the graft.
Fusing an unstable, often arthritic human lumbar spine for relief of back and leg pain is a common spine surgeon’s challenge. Doctor Prolo has recently reported his surgical treatment over 25 years (1981-2006) with long-term, dedicated follow-up of patients: 321 patients underwent 339 posterior lumbar interbody fusions with human cadaver bone only. Successful anatomic fusion was documented by radiographs in 96% of patients with 87% clinical results excellent (52%) or good (35%), determined on the nonparametric Occupational/Functional Clinical Outcome Scale (Prolo Scale) he first reported in 1986. Fusion rate from this long-term, carefully documented study achieved statistical significance exceeding any other rates published with equally rigorous documentation.